Table V.
ID | Array glycan | Experimental bindinga |
---|---|---|
1 | Galβ1-3GalNAcα-Sp8 | Yes |
2 | Galβ1-3GalNAcα-Sp16 | Nod |
3 | Galβ1-3GalNAcα-Sp14 | Nod |
4 | Neu5Acα2-6(Galβ1-3)GalNAcα-Sp8 | Yes |
5 | Neu5Acα2-6(Galβ1-3)GalNAcα-Sp14 | Nod |
6 | GlcNAcβ1-6(Galβ1-3)GalNAcα-Sp8 | Yes |
7 | GlcNAcβ1-6(Galβ1-3)GalNAcα-Sp14 | Nod |
8 | Galβ1-4GlcNAcβ1-6(Galβ1-3)GalNAcα-Sp8 | Yes |
9 | Galβ1-4GlcNAcβ1-6(Galβ1-3)GalNAcα-Sp14 | Nod |
10 | Neu5Acβ2-6(Galβ1-3)GalNAcα-Sp8 | Yes |
11 | KDNα2-3Galβ1-3GalNAcα-Sp14 | No |
12 | Neu5Acα2-6(Neu5Acα2-3Galβ1-3)GalNAcα-Sp14 | No |
13 | Neu5Acα2-3Galβ1-4GlcNAcβ1-6(Neu5Acα2-3Galβ1-3)GalNAcα-Sp14 | No |
14 | Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-6(Galβ1-3)GalNAcα-Sp14 | Nod |
15 | Fucα1-2Galβ1-3GalNAcα1-3(Fucα1-2)Galβ1-4Glcβ-Sp0 | No |
16 | GlcNAcβ1-2Galβ1-3GalNAcα-Sp8 | No |
17 | Neu5Acα2-3Galβ1-3GalNAcα-Sp8 | No |
18 | Fucα1-2Galβ1-3GalNAcα-Sp14 | No |
19 | Neu5Acα2-3Galβ1-3GalNAcα-Sp14 | No |
20 | Neu5Acα2-6(Neu5Acα2-3Galβ1-3)GalNAcα-Sp8 | No |
21 | Neu5Acα2-3Galβ1-4GlcNAcβ1-6(Galβ1-3)GalNAcα-Sp14 | Nod |
22 | (3S)Galβ1-3GalNAcα-Sp8 | No |
23 | Fucα1-2Galβ1-3GalNAcα-Sp8 | No |
24 | Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-6(Neu5Acα2-3Galβ1-3)GalNAcb-Sp14 | No |
25 | Fucα1-2Galβ1-3GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ-Sp0 | No |
26 | GalNAcα1-3(Fucα1-2)Galβ1-3GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ-Sp0 | No |
27 | GlcNAcβ1-3Galβ1-3GalNAcα-Sp8 | No |
28 | Galβ1-3GalNAcα1-3(Fucα1-2)Galβ1-4Glcc-Sp0 | No |
29 | GlcNAcα1-4Galβ1-3GalNAcb-Sp14 | No |
30 | Galβ1-3GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcc-Sp0 | No |
31 | 6S(Neu5Acα2-3Galβ1-3)GalNAcα-Sp8 | No |
aBinders defined as having greater than 10% of maximal RFUs at each protein concentrations (0.1, 5 and 200 μg/mL).
bReducing anomeric configuration undefined on the CFG array, α-configuration assumed for the CCG analysis.
cReducing anomeric configuration undefined on the CFG array, both configurations tested in the CCG analysis.
dHighlighted in grey are the predicted false negatives from the v4.0 CFG array screening of JAA-F11.